Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts.
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million.
Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company.
In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim